For: | Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619 [PMID: 38179402 DOI: 10.5306/wjco.v14.i12.606] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm |
Number | Citing Articles |
1 |
Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio, Luisa Fernanda Rivera-Moncada. Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. World Journal of Clinical Oncology 2024; 15(5): 587-590 doi: 10.5306/wjco.v15.i5.587
|
2 |
Elisa Aquilanti, Elizabeth Herrity, Lakshmi Nayak. Novel Therapies for Primary Central Nervous System Lymphomas. Current Neurology and Neuroscience Reports 2024; 24(12): 621 doi: 10.1007/s11910-024-01376-5
|
3 |
Wenhua Wang, Bingyi Wang, Yifei Sun, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Zheng Song, Wei Li, Lanfang Li, Xianhuo Wang, Huilai Zhang. Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1579483
|
4 |
Michel Wakim, Mariana Mezher, Ariel Perez-Perez, Arun Maharaj, Yazmin Odia, Manmeet Ahluwalia, Yuliya Linhares. Novel Therapies in Primary Central Nervous System Lymphoma. Clinical Pharmacology: Advances and Applications 2025; : 97 doi: 10.2147/CPAA.S501065
|
5 |
Budhi Singh Yadav. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma. World Journal of Clinical Oncology 2024; 15(3): 371-374 doi: 10.5306/wjco.v15.i3.371
|